Tada et al. (203) tested a TAA-pulsed DC vaccine (AFP, GPC3, MAGE-1) in five advanced HCC patients, showing safety, TAA-specific T cell responses in all patients, and a clinical response in one patient. This evidence concerns the gene GPC3 and hepatocellular carcinoma.